Eric Dishman Headshot
Report a problem with this profile
[email protected]

Eric Dishman    

Director of the All of Us Research Program

Eric Dishman is the director of the All of Us Research Program. In this role, he leads the agency’s efforts to build a national research program of 1 million or more U.S. participants to advance precision medicine. Previously, Eric was an Intel fellow and vice president of the Health and Life Sciences Group at Intel Corporation, where he was responsible for driving global strategy, research and development, product and platform development, and policy initiatives for health and life science solutions. His organization focused on growth opportunities for Intel in health information technology, genomics and personalized medicine, consumer wellness, and care coordination technologies.

Eric is widely recognized as a global leader in health care innovation with specific expertise in home and community-based technologies and services for chronic disease management and independent living. Trained as a social scientist, Eric is known for pioneering innovation techniques that incorporate anthropology, ethnography, and other social science methods into the development of new technologies. He also brings his own experience as a cancer patient for 23 years—finally cured thanks to precision medicine—to drive a person-centric view of health care transformation. Eric shares crucial updates about the program on the website in the Director’s Corner. He also shares news and program information on his Twitter account.


Eric Dishman wants precision medicine to move from personal to universal

BOSTON – In 1989, when he was a 19-years-old college student, Eric Dishman was diagnosed with a rare kidney cancer and given just months to live.

Instead he spent the next 23 years visting 17 hospitals and clinics across eight states, receiving exhaustive and exhausting treatment – more than 60 rounds of chemotherapy, radiation and/or immunotherapy – than ended up costing more than $6 million ...

1 million patient cohort being prepared to fuel precision medicine knowledge base

The promise of precision medicine is starting to be realized. The combination of patient medical records and genomic data is proving to be a potent source of data for clinicians as they apply analytical tools in the search for better treatments.

But one factor holds back many new initiatives. The data available for analysis is limited to the records of patients who are participating in any given trial. For precision medicine to reach its true potential, the number of patient datasets will need to grow dramatically ...

Brainstorm Health Daily: June 13, 2017

“It is the policy of this state that the deliberative process of governmental bodies shall be open to the public during meetings.” So begins Section 36-25A-1 of the Alabama code. South Carolina’s General Assembly has determined “that it is vital in a democratic society that public business be performed in an open and public manner so that citizens shall be advised of the performance of public officials and of the decisions that are reached in public activity and in the formulation of public policy" ...

Related Speakers View all

More like Eric